The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RNA | +50.04% | +139.66% | +19.1% | +148% |
| S&P | +14.08% | +93.57% | +14.12% | +125% |
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Eli Lilly, Johnson & Johnson, and AbbVie command the healthcare sector.
Novartis is set to boost its developmental pipeline with this acquisition.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $12.48M | 434.0% |
| Gross Profit | $11.42M | 602.3% |
| Gross Margin | 91.54% | 21.9% |
| Market Cap | $6.36B | 18.2% |
| Market Cap / Employee | $16.26M | 0.0% |
| Employees | 391 | 54.5% |
| Net Income | -$174.44M | -117.0% |
| EBITDA | -$187.75M | -92.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $350.16M | -5.4% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $46.00M | 1111.5% |
| Short Term Debt | $3.97M | 4.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -29.13% | -3.8% |
| Return On Invested Capital | -27.75% | 2.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$156.89M | -133.0% |
| Operating Free Cash Flow | -$156.17M | -138.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.30 | 2.48 | 2.58 | 4.41 | 7.35% |
| Price to Sales | 342.91 | 427.35 | 343.11 | 287.91 | -48.60% |
| Price to Tangible Book Value | 2.30 | 2.48 | 2.58 | 4.41 | 7.35% |
| Enterprise Value to EBITDA | -18.64 | -18.67 | -14.70 | -22.28 | -46.88% |
| Return on Equity | -33.5% | -34.2% | -37.8% | -32.4% | 16.86% |
| Total Debt | $6.80M | $5.97M | $5.14M | $49.97M | 557.36% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
